{"title":"Differentiation of non-ST-segment elevation myocardial infarction from unstable angina using coronary computed tomography angiography: the role of imaging features and pericoronary adipose tissue radiomics.","authors":"Yang Lu, Qing Wang, Haifeng Liu, Qi Liu, Siqi Wang, Wei Xing","doi":"10.5603/cj.98559","DOIUrl":"10.5603/cj.98559","url":null,"abstract":"<p><strong>Background: </strong>To ascertain the diagnostic value of radiomic features of pericoronary adipose tissue (PCAT) and other coronary computed tomography angiography (CCTA) parameters for differentiating non-ST-segment-elevation myocardial infarction (NSTEMI) from unstable angina (UA).</p><p><strong>Methods: </strong>This study included NSTEMI and UA patients (n = 102 each). The radiomic features of PCAT were selected according to the intraclass correlation coefficient, Pearson's coefficient, the t test, and least absolute shrinkage and selection operator. Six classifiers-random forest, support vector machine, naive Bayes, K-nearest neighbors, extreme gradient boosting, and light gradient boosting machine (LightGBM)-were used to build radiomics models, and the best were selected. Four CCTA parameter models, encapsulating plaque parameters (model 1), plaque parameters + fatty attenuation index (FAI) (model 2), plaque parameters + CT fractional flow reserve (CT-FFR) (model 3), and plaque parameters + CT-FFR + FAI (model 4), were constructed. Finally, we established a fusion model (nomogram) with all CCTA parameters and radiomics model scores. All models were compared regarding their performance.</p><p><strong>Results: </strong>The LightGBM radiomics model achieved the highest AUC. Among CCTA parameter models, only model 4 achieved a predictive performance similar to that of the radiomics model in the training and test cohorts (AUC = 0.904 vs. 0.898 and 0.860 vs. 0.877). The combined model (nomogram) showed greater predictive efficacy (AUC = 0.963, 0.910) than model 4 or the radiomics model.</p><p><strong>Conclusion: </strong>The PCAT-based radiomics model accurately distinguishes between NSTEMI and UA, with similar diagnostic performance as the model that combined all the significant CCTA parameters. The nomogram integrating CCTA parameters and the radiomic score has good clinical application prospects.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Krzysztof J Filipiak, Matteo Cameli, Santiago J Freire, Rahima Gabulova, Gulnoz Khamidullaeva, Anna Tomaszuk-Kazberuk, Agnieszka Kuzior, Francisco Javier Martinez-Martin, Ulvi Mirzoyev, Ulugbek Nizamov, Nguyen Van Tan, Aleksandra Gąsecka
{"title":"EASY OR NOT. European-Asian Six countries Yearly consensus On Recent guidelines: arterial hypertension, atrial fibrillation, chronic coronary syndromes, and peripheral artery diseases. Novel Or conventional Treatment options for these patients. Position Paper 2024.","authors":"Krzysztof J Filipiak, Matteo Cameli, Santiago J Freire, Rahima Gabulova, Gulnoz Khamidullaeva, Anna Tomaszuk-Kazberuk, Agnieszka Kuzior, Francisco Javier Martinez-Martin, Ulvi Mirzoyev, Ulugbek Nizamov, Nguyen Van Tan, Aleksandra Gąsecka","doi":"10.5603/cj.105140","DOIUrl":"https://doi.org/10.5603/cj.105140","url":null,"abstract":"<p><p>The 2024 guidelines of the European Society of Cardiology (ESC) refer to four very important therapeutic areas: arterial hypertension, atrial fibrillation, chronic coronary syndromes and peripheral artery disease. The ESC countries and their institutional members share a common goal of reducing the burden of cardiovascular diseases, which remain the leading cause of death worldwide. Experts from these six countries - three from Europe and three from Asia - gathered at the annual meeting to briefly present the epidemiological situation regarding selected issues addressed in the 2024 ESC guidelines, and to create a document highlighting the significant progress in pharmacotherapy. The new guidelines allow us to identify particularly important therapeutic areas and unmet pharmaceutical needs within the four treatment guidelines developed by the ESC in 2024. While discussing each of these four documents, 10 subjectively selected points were chosen to highlight what should be kept in mind in daily clinical practice. Altogether, a range of all-risk categories are represented, and the observations made in this position paper are of a universal nature.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandra Żuk-Łapan, Olga Jakubik, Michał Pałuchowski, Magdalena Gajewska, Sylwester Rogula, Michał Łomiak, Aleksandra Gąsecka
{"title":"Targeting factor XI as a compromise between thrombosis and bleeding.","authors":"Aleksandra Żuk-Łapan, Olga Jakubik, Michał Pałuchowski, Magdalena Gajewska, Sylwester Rogula, Michał Łomiak, Aleksandra Gąsecka","doi":"10.5603/cj.102145","DOIUrl":"https://doi.org/10.5603/cj.102145","url":null,"abstract":"<p><p>Thromboembolic diseases have long been a leading cause of morbidity and mortality, necessitating advances in anticoagulant drugs. Heparins, vitamin K inhibitors, and direct oral anticoagulants (DOACs) are well-established drug classes that help prevent thromboembolic complications. While effective, they pose significant risks during long-term therapy, including bleeding, osteoporosis, heparin-induced thrombocytopenia, and the need for frequent monitoring and dose adjustments. Factor XI (FXI) inhibitors represent an innovative approach in anticoagulation therapy, aiming to balance thromboembolic events with the risk of bleeding complications. They include: a) orally administered small molecule inhibitors such as milvexian and asundexian; b) monoclonal antibodies such as abelacimab, osocimab, and xisomab, which specifically bind and inactivate FXI; c) FXI-antisense oligonucleotide (FXI-ASO), which downregulate FXI synthesis at the mRNA level and reduce plasma FXI concentrations. Available data indicate that FXI inhibitors decrease the risk of thromboembolic events and are associated with a lower incidence of major bleeding than current gold standard methods. Hence, FXI inhibitors may become the preferred anticoagulant class, especially for patients with elevated bleeding risk. Their development is an important step in the history of anticoagulant therapy, striving to find a balance between preventing thromboembolism and reducing bleeding risk, ultimately improving patient outcomes. In this context, a discussion on the characteristics of FXI inhibitors, a summary on data regarding the efficacy and safety of FXI inhibitors based on preclinical and clinical studies, and an outline of future perspectives regarding therapeutic strategies of FXI inhibition in venous thrombosis are presented in this study.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Boris Dzudovic, Ivica Djuric, Jovan Matijasevic, Zoran Jovic, Szymon Darocha, Slobodan Obradovic
{"title":"Coronary-type stent implantation in chronic thromboembolic pulmonary hypertension: a national registry case series.","authors":"Boris Dzudovic, Ivica Djuric, Jovan Matijasevic, Zoran Jovic, Szymon Darocha, Slobodan Obradovic","doi":"10.5603/cj.103142","DOIUrl":"https://doi.org/10.5603/cj.103142","url":null,"abstract":"<p><strong>Background: </strong>Balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) are established treatments for chronic thromboembolic pulmonary hypertension (CTEPH). In cases where BPA is ineffective, stent implantation emerges as salvage therapy. However, stent implantation during BPA remains a subject of debate.</p><p><strong>Methods: </strong>This seven-year case series in Serbia, where PEA is unavailable, examines outcomes in 10 CTEPH patients undergoing BPA with coronary-type stent implantation during BPA. Objectives include assessing the feasibility, safety, and efficacy of this combined approach, identifying optimal patient selection criteria. Criteria for stent placement included persistent unsatisfactory flow post-multiple balloon dilatations. Follow-up assessments were via repeat pulmonary angiography.</p><p><strong>Results: </strong>Stents were successfully deployed, demonstrating sustained patency in 14 of 15 stents over an average 21.5-month (ranging from 11 up to 82 months) follow-up. Outcomes revealed significant reductions in mean pulmonary artery pressure, improvements in WHO Functional Class, and enhanced 6-minute walking distance. For the first 6 months, patients received daily clopidogrel 75 mg and rivaroxaban 15 mg, without significant bleeding. Dual therapy for pulmonary hypertension was consistently upheld. During the follow-up period, no stent thrombosis, restenosis, or other severe acute or chronic complications were observed; however, in one case, additional balloon stent post-dilatation was required.</p><p><strong>Conclusion: </strong>Coronary-type stent implantation during BPA for selected CTEPH patients, though not a primary treatment, proved valuable, offering a potential solution when BPA alone falls short. This case series emphasizes the need to refine patient selection criteria for this emerging therapeutic avenue.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleksandra Gąsecka, Patryk Pindlowski, Mateusz Szczerba, Jakub M Zimodro, Ewelina Błażejowska, Arkadiusz Pietrasik, Maciej Lesiak, Mario Iannaccone, José P S Henriques, René J van der Schaaf, Janusz Kochman
{"title":"Drug-coated balloons in percutaneous coronary interventions: existing evidence and emerging hopes.","authors":"Aleksandra Gąsecka, Patryk Pindlowski, Mateusz Szczerba, Jakub M Zimodro, Ewelina Błażejowska, Arkadiusz Pietrasik, Maciej Lesiak, Mario Iannaccone, José P S Henriques, René J van der Schaaf, Janusz Kochman","doi":"10.5603/cj.101393","DOIUrl":"https://doi.org/10.5603/cj.101393","url":null,"abstract":"<p><p>Drug-coated balloons (DCB) have been developed as an alternative to drug-eluting stents (DES) as a part of the \"leave nothing behind\" strategy following percutaneous coronary interventions (PCI). DCBs facilitate revascularization and delivery of an antiproliferative agent directly to a coronary artery lesion, without the need for DES implantation. Subsequently, DCBs promote positive vascular remodeling and allow for a shorter duration of dual antiplatelet therapy. Since the first reports on the successful treatment of coronary in-stent restenosis (ISR) with paclitaxel-coated balloon catheters in the year 2006, the use of DCBs has been growing, driven by reports of DCB application to treat ISR, bifurcation lesions, and small vessel disease. Contemporary clinical trials evaluating DCBs in large vessel disease and chronic total occlusions might further expand the indications for this technology. Attention has also been brought to the use of DCBs in patients with diabetes mellitus and acute coronary syndrome, especially those at high bleeding risk. This review aims to discuss the existing evidence and emerging hopes associated with DCBs, including technical aspects of DCB PCI and the use of DCBs in different clinical scenarios.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wojciech J Skorupski, Arkadiusz Pietrasik, Aleksandra Gąsecka, Jerzy Sacha, Tomasz Pawłowski, Gabriel Bielawski, Wojciech Balak, Adam Sukiennik, Paulina Burzyńska, Adam Witkowski, Mateusz Warniełło, Łukasz Rzeszutko, Stanisław Bartuś, Artur Pawlik, Mateusz Kaczyński, Robert Gil, Wiktor Kuliczkowski, Krzysztof Reczuch, Marcin Protasiewicz, Jacek Legutko, Paweł Kleczyński, Piotr Wańczura, Sebastian Gurba, Anna Kochanowska, Michał Łomiak, Maciej Krajsman, Włodzimierz Skorupski, Maciej Zarębiński, Piotr Pawluczuk, Szymon Włodarczak, Adrian Włodarczak, Krzysztof Ściborski, Artur Telichowski, Mieszko Pluciński, Jarosław Hiczkiewicz, Karolina Konsek, Michał Hawranek, Mariusz Gąsior, Jan Peruga, Marcin Fiutowski, Robert Romanek, Piotr Kasprzyk, Dariusz Ciećwierz, Andrzej Ochała, Wojciech Wojakowski, Janusz Kochman, Maciej Lesiak, Marek Grygier
{"title":"Short- and long-term outcomes of Impella-protected, high-risk, elective PCI in patients with multivessel coronary disease and low ejection fraction - Polish Impella Registry.","authors":"Wojciech J Skorupski, Arkadiusz Pietrasik, Aleksandra Gąsecka, Jerzy Sacha, Tomasz Pawłowski, Gabriel Bielawski, Wojciech Balak, Adam Sukiennik, Paulina Burzyńska, Adam Witkowski, Mateusz Warniełło, Łukasz Rzeszutko, Stanisław Bartuś, Artur Pawlik, Mateusz Kaczyński, Robert Gil, Wiktor Kuliczkowski, Krzysztof Reczuch, Marcin Protasiewicz, Jacek Legutko, Paweł Kleczyński, Piotr Wańczura, Sebastian Gurba, Anna Kochanowska, Michał Łomiak, Maciej Krajsman, Włodzimierz Skorupski, Maciej Zarębiński, Piotr Pawluczuk, Szymon Włodarczak, Adrian Włodarczak, Krzysztof Ściborski, Artur Telichowski, Mieszko Pluciński, Jarosław Hiczkiewicz, Karolina Konsek, Michał Hawranek, Mariusz Gąsior, Jan Peruga, Marcin Fiutowski, Robert Romanek, Piotr Kasprzyk, Dariusz Ciećwierz, Andrzej Ochała, Wojciech Wojakowski, Janusz Kochman, Maciej Lesiak, Marek Grygier","doi":"10.5603/cj.103336","DOIUrl":"https://doi.org/10.5603/cj.103336","url":null,"abstract":"<p><strong>Background: </strong>The Impella percutaneous mechanical circulatory support device provides improved support in treating patients with high-risk percutaneous coronary interventions (HR-PCI) or in cardiogenic shock. IMPELLA-PL is a multicenter registry developed to share clinical data and experiences using Impella technology in Poland. The retrospective analysis conducted in this study aims to fill the knowledge gap of Impella performance in patients with multivessel coronary artery disease (CAD) and depressed left ventricular ejection fraction (EF) (≤30%) treated with HR-PCI.</p><p><strong>Methods: </strong>Retrospective data were analyzed from patients presenting with multivessel coronary disease and low EF treated with Impella CP collected from 20 Polish interventional cardiology centers registered with IMPELLA-PL to assess the safety and efficacy in short- and long-term clinical outcomes.</p><p><strong>Results: </strong>A total of 115 patients with low EF received Impella CP support during HR-PCI. The success rate of Impella supported HR-PCI was high (99.1%) with an average hospital stay of 15.6 ± 10.7 days. The right femoral artery was the most common access (55.7%) followed by the left femoral artery (37.4%). The in-hospital mortality rate was 6.1%, and the all-cause mortality rate at one year was 13.9%.</p><p><strong>Conclusions: </strong>High-risk PCI with Impella CP periprocedural support was safe and effective in patients with low EF (≤30%). The all-cause mortality rate (6.1% and 13.9%, respectively, for in-hospital and at 12-months) was comparable with other Impella registries.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nadine Molitor, Vera Graup, Daniel Hofer, Pascal Rüegg, Deniza Avdi, Ardan M Saguner, Alexander Breitenstein, Jan Steffel
{"title":"The effect of an antibacterial envelope on cardiac implantable device-related infection - A real-world analysis from a tertiary center.","authors":"Nadine Molitor, Vera Graup, Daniel Hofer, Pascal Rüegg, Deniza Avdi, Ardan M Saguner, Alexander Breitenstein, Jan Steffel","doi":"10.5603/cj.100458","DOIUrl":"https://doi.org/10.5603/cj.100458","url":null,"abstract":"<p><strong>Background: </strong>Infections related to cardiac implantable electronic devices (CIED) are associated with significant morbidity and mortality. Antibiotic-eluting envelopes have been introduced as a technology to prevent CIED infections. The aim of this study was to evaluate the effectiveness of the antibacterial envelope in the real-world population of a tertiary center.</p><p><strong>Methods: </strong>This cohort study includes consecutively enrolled patients undergoing a device procedure from 01/2014 to 12/2020 at the University Hospital in Zurich. During period A (01/2014-12/2019) antibacterial envelopes were not used, whereas during period B (01/2020-12/2020) antibacterial envelopes were used in all device interventions. Follow-up was conducted by assessing all available patient records from patient visits and hospitalization.</p><p><strong>Results: </strong>1757 patients (male 70.5%, mean age 67.1 ± 16 years), were analyzed during a follow-up of 24 months. In 302 patients (17.2%) an antibacterial envelope was used. The overall occurrence of a device infection was low (n = 15, 0.85%). Factors that were associated with the incidence of an infection were not undergoing a primary implantation procedure (p = 0.024) and a CRT-P/D intervention (p = 0.022). There was no difference in the rate of infection between patients in whom a bacterial envelope was implanted vs. those in whom it was not used (0.6 vs. 0.9%, p = 0.693).</p><p><strong>Conclusion: </strong>In a contemporary cohort of consecutive, unselected patients undergoing a device intervention at a large tertiary care center, the rate of device infection was low and not significantly different with vs. without the use of an antibacterial envelope. The data have important practical as well as economic implications for physicians performing such procedures.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2025-03-10DOI: 10.5603/cj.102844
Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal
{"title":"Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study.","authors":"Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal","doi":"10.5603/cj.102844","DOIUrl":"10.5603/cj.102844","url":null,"abstract":"<p><strong>Background: </strong>Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI. M: ETHODS: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.</p><p><strong>Results: </strong>Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442-59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).</p><p><strong>Conclusions: </strong>Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"164-174"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiology journalPub Date : 2025-01-01Epub Date: 2024-11-26DOI: 10.5603/cj.99142
Andrzej Głowniak, Anna Drelich-Zbroja, Adam Tarkowski, Paweł Marzęda, Katarzyna Wojewoda, Katarzyna Wysokińska, Anna Wysocka, Monika Miazga, Anna Jaroszyńska, Krzysztof Kaczmarek, Andrzej Jaroszyński, Michał Orczykowski
{"title":"Silent cerebral ischemic lesions in ablation-naïve patients with non-valvular atrial fibrillation: Does the pulmonary vein anatomy matter?","authors":"Andrzej Głowniak, Anna Drelich-Zbroja, Adam Tarkowski, Paweł Marzęda, Katarzyna Wojewoda, Katarzyna Wysokińska, Anna Wysocka, Monika Miazga, Anna Jaroszyńska, Krzysztof Kaczmarek, Andrzej Jaroszyński, Michał Orczykowski","doi":"10.5603/cj.99142","DOIUrl":"10.5603/cj.99142","url":null,"abstract":"<p><strong>Background: </strong>Silent cerebral ischemic lesions (SCILs) detected by magnetic resonance imaging (MRI) can precede symptomatic stroke, the risk of which is increased five-fold in atrial fibrillation (AF) patients. In our study, we aimed to evaluate the initial incidence of SCILs in the population of patients referred for ablation due to symptomatic AF and to identify possible risk factors.</p><p><strong>Methods: </strong>A total of 110 patients, with a mean age (SD) of 59.9 (9.4) years, referred for ablation, were included in the study. In all patients, MRI was performed before the procedure to evaluate the incidence of SCILs in the ablation-naïve patients.</p><p><strong>Results: </strong>MRI revealed preexisting SCIL in 81/110 patients (73.6%). Notably, SCILs were found in all patients with CHA₂DS₂-VASc score ≥ 4. In univariable analysis, age (p < 0.001), CHA₂DS₂-VASc score (p = 0.001), hypertension (p = 0.01), and anticoagulation duration (p = 0.023) were identified as significant risk factors for SCILs, while the presence of anatomical variants of left-sided common pulmonary veins trunk (LCPV) had negative prognostic value (p = 0.026). Multivariable logistic regression analysis identified age (p < 0.001) as the risk factor of preexisting SCILs, whereas the presence of LCPV trunk was associated with significantly lower (p = 0.005) SCILs incidence.</p><p><strong>Conclusions: </strong>Silent cerebral ischemic lesions detected in MRI are frequent in the population of patients with non-valvular AF. The incidence of SCILs is higher in patients with long history of arrhythmia and higher CHA₂DS₂-VASc score. The relationship between the anatomy of pulmonary veins and the incidence of SCILs needs further investigation.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}